Fulgent Reports Third Quarter 2025 Financial Results

Core Insights - Fulgent Genetics, Inc. reported its third quarter 2025 financial results, showing continued growth in its laboratory services and therapeutic development businesses, with a notable focus on clinical trials for cancer treatments [2][4]. Financial Performance - Revenue for Q3 2025 was $84.1 million, representing a 17% increase year-over-year [5][6]. - The company reported a GAAP loss of $6.6 million, or ($0.21) per share, while non-GAAP income was $4.5 million, or $0.14 per share [5][6]. - Adjusted EBITDA for the quarter was $0.7 million [6]. - For the full year 2025, Fulgent raised its revenue guidance to $325.0 million [5]. Operational Highlights - The company is advancing its clinical trials, particularly with FID-007, which has shown meaningful efficacy in treating head and neck cancer patients [4]. - Fulgent has initiated phase one dosing escalation for FID-022, showcasing the capabilities of its nano delivery technology platform [4]. Outlook - Fulgent expects to close 2025 with a healthy balance sheet, projecting a GAAP loss of approximately ($1.70) per share and non-GAAP income of $0.30 per share for the year [5][7]. - The company ended Q3 2025 with $787.7 million in cash, cash equivalents, restricted cash, and investments in marketable securities [5].